San Diego, CA, USA, August 1st, 2018 – Steminent Biotherapeutics Inc. (“Steminent” or “Company”) a private, clinical-stage cell-therapy company with offices in Taiwan, San Diego and Shanghai, is pleased to announce that the Clinical Trial Notification (“CTN”), submitted by their Japan partner; ReproCELL, to the Japan Pharmaceuticals and Medical Device Agency (“PMDA”) for a Stemchymal® SCA Phase II clinical trial for Polyglutamine Spinocerebellar Ataxia (“PolyQ SCA”) has been approved. This is another key milestone for Steminent’s international Stemchymal® SCA Phase II clinical development program with trials now moving ahead in Taiwan, US, and Japan. [Read more…]
Parkinson’s Disease Clinical Trial to Launch in Japan | iPS Cell Trial
Japan will continue its dominance with iPS cell clinical trials with the launch of a physician-lead trial for Parkinson’s disease. In its July 2018 press announcement, Kyoto University announced that its University Hospital and the Center for iPS Cell Research and Application (CiRA) will launch the world’s first clinical trial for Parkinson’s disease to utilize an induced pluripotent stem cell (iPS cell) derived therapeutic product.
Existing iPS Cell Trials
This newest iPS cell trial represents only the third iPS cell trial to be undertaken worldwide. The other existing iPS cell trials are being conducted by the RIKEN Center for Developmental Biology (CDC) and Cynata Therapeutics (ASX:CYP), respectively. [Read more…]
RichSource Stem Cells, Inc. Announces Non-Invasive Breakthrough Product RICHGEN
August 1, 2018 – Charleston, SC, USA – RichSource Stem Cells, Inc. (RichSource), a leader in the business development and distribution of human tissue allograft combination products and membranes, announced today its own brand product line: RICHGEN. With the introduction of this breakthrough line, the industry is no longer limited to single material post-birth, multipotent cellular products. Available throughout the U.S., the RICHGEN product line is backed by an experienced nationwide team of RichSource Area Vice Presidents who can educate, train and provide support to physician practices and networks. Additionally, RichSource’s simplified and more effective treatment protocols helps to optimize practices and patient results. [Read more…]
Steminent Announces FDA Approval of IND for Phase II Clinical Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia
San Diego, CA, USA, July 18th, 2018 – Steminent Biotherapeutics Inc. (“Steminent” or “Company”) a private, clinical-stage cell-therapy company with offices in Taiwan, San Diego and Shanghai, is pleased to announce that the United States Food and Drug Administration (“FDA”) has raised no objections to the Company’s Investigational New Drug (“IND”) application. This allows the Company to initiate its Phase II clinical trial for polyglutamine spinocerebellar ataxia (“PolyQ SCA”) to enroll patients at clinical sites in the United States. This is a key milestone for the Company’s international Stemchymal® SCA Phase II clinical trials program. [Read more…]
How Much Does Cord Blood Banking Cost?
Cord blood banking is an option available to most any parent after the birth of their child. There are proven benefits to the stem cells you can easily collect and store through the birthing process, although this is generally not common knowledge. While the cost of storing cord blood can often be more than parents want to pay, it might be a good idea to know what your options are before you decide.
This article will provide you with answers to some of the key questions about cord blood banking and stem cells in general. Read ahead to better understand why you might want to consider cord blood banking. [Read more…]
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 202
- Next Page »